Mammary analogue secretory carcinoma (MASC) is a newly recognized salivary gland neoplasm that shares characteristics with secretory carcinoma of the breast. Since its first description by Skalova et al in 2010, many reviews have been published. While current research has described specific immunohistochemistry and genetic translocations of MASC, there is much in terms of management that remains unknown. We present a unique case of a 20-year-old male with a parotid tumor that was reclassified as MASC based on its histologic and immunohistochemical findings, and we describe our management.
Introduction
With the recent recognition of mammary analogue secretory carcinoma (MASC), many previously diagnosed acinic cell carcinomas and adenocarcinomas not otherwise specified (NOS) have been reclassified to MASC based on specific histologic, immunohistochemical, and genetic findings. MASC is a newly described salivary gland neoplasm characterized by an ETV6 translocation and shares histologic and immunohistochemical findings similar to secretory carcinoma of the breast [1] . In this case report, we discuss the rare case of MASC in a 20-year-old male with a parotid tumor.
Case Report
A 20-year-old male with no significant past medical history presented with a 3-year history of a left-sided face mass along the angle of the jaw, which he stated had progressively increased in size. The patient denied tenderness, fever, chills, or any recent weight loss. The mass was solid, mobile, and measured approximately 2 × 2 cm in size. A volumetric computed tomography (CT) scan of the neck demonstrated a centrally fluid-attenuated cystic structure measuring 2.2 × 2.2 × 2.1 cm in the tail of the parotid gland (Fig. 1) . A formal excision of the cystic structure was performed, and no pathological nodes were detected in the neck. The tumor was ultimately classified as an MASC of the salivary gland. Postoperative radiotherapy was not recommended, and at an in-office follow-up, the patient remained without evidence of disease.
Discussion
MASC is a newly recognized salivary gland neoplasm first characterized in 2010 that shares similar histopathology and genetics with secretory carcinoma of the breast. MASC expresses the t(12;15) (p13;q25) translocation resulting in the 
ETV6-NTRK3 fusion gene, which potentiates tyrosine kinase activity and promotes oncogenesis [2] [3] [4] . MASC is commonly a solitary, well-circumscribed, encapsulated mass located in the parotid gland, but it may also develop from the oral cavity, submandibular gland, or the accessory parotid glands [3, 5] . It is commonly detected incidentally on physical examination and presents as a slowly enlarging and painless nodule [3] . One patient was found to have facial paralysis with bulky growth of a parotid gland tumor [3] . Previously, MASC was classified with other low-grade salivary carcinomas, most commonly mislabeled as acinic cell carcinoma (ACC) or ADC-NOS [1, 3] . Unlike ACC, MASC has no gender preference, a mean incidence age of 40, and the potential for lymph node metastasis [3] . Additionally, MASC is reactive to S100 protein and mammaglobin and unreactive to DOG1 [1, 6] . Other histological features of MASC include cystic, tubular, and/or papillary architecture, eosinophilic vacuolated cytoplasm, intraluminal or intracellular colloid-like secretions, and pale nuclei [3] . Histopathology of our patient's parotid mass revealed a cystic lesion lined with cuboidal to columnar epithelium (Fig.  2a, b) . There was a focus of cystic proliferation surrounded by a fibrous wall. The lumen and the wall of the cyst focally contained hemorrhagic material and foam cells. From the histopathological findings, the differential diagnoses included cystadenoma of the parotid gland, salivary duct cyst with hyperplasia, and duct ectasia with focal epithelial proliferation. Immunohistochemistry was subsequently performed, and the tumor was found to be regionally positive for S100 protein and mammaglobin and negative for DOG1. The parotid tumor was diagnosed as MASC, further emphasizing the role that histology and immunohistochemistry play in the recognition of MASC. Fluorescence in situ hybridization (FISH) for ETV6 gene rearrangement, characteristic of MASC, can be used as a supplement but it is not necessary nor definitive for diagnosis [3, 7] .
Standard of care for low-grade malignant salivary gland cancers is surgical resection. Due to limited information regarding the prognostic behavior of MASC, the benefits of neck dissection and postoperative radiotherapy are still under consideration [3] .
Conclusion
Since the first description of MASC in 2010, only 92 cases have been reported, highlighting this newly classified carcinoma [3, 5] . In addition, 19% of parotid gland tumors and 79% of extra-parotid gland tumors originally classified as ACC were reclassified as MASC by Bishop [5] . While there are specific immunohistochemical and genetic characteristics specific to MASC, the clinical behavior, prognosis, and treatment of this analogue are limited. 
